{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:34:09Z","timestamp":1778600049339,"version":"3.51.4"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dermatol"],"published-print":{"date-parts":[[2003,1,1]]},"DOI":"10.1001\/archderm.139.1.33","type":"journal-article","created":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T13:47:51Z","timestamp":1078148871000},"page":"33","source":"Crossref","is-referenced-by-count":305,"title":["Intravenous Immunoglobulin Treatment for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis"],"prefix":"10.1001","volume":"139","author":[{"given":"Nicolas","family":"Bachot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Revuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Roujeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"key":"ref-dst10216-1","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs.","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"ref-dst10216-2","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD35 with human intravenous immunoglobulin.","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"ref-dst10216-3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1046\/j.1523-1747.2000.00037.x","article-title":"Death receptors in cutaneous biology and disease.","volume":"115","author":"Werhrli","year":"2000","journal-title":"J Invest Dermatol"},{"key":"ref-dst10216-4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/archderm.136.3.410","article-title":"Improving the outcome of patients with toxic epidermal necrolysis and Stevens-Johnson syndrome.","volume":"136","author":"Stern","year":"2000","journal-title":"Arch Dermatol"},{"key":"ref-dst10216-5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine.","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"ref-dst10216-6","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/jde.1999.26.issue-11","article-title":"Treatment of severe drug eruptions.","volume":"26","author":"Roujeau","year":"1999","journal-title":"J Dermatol"},{"key":"ref-dst10216-7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN a severity-of-illness score for toxic epidermal necrolysis.","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"ref-dst10216-8","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(97)11369-1","article-title":"Toxic epidermal necrolysis.","volume":"351","author":"Becker","year":"1998","journal-title":"Lancet"},{"key":"ref-dst10216-9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/0190-9622(92)70082-Q","article-title":"Drug induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus.","volume":"26","author":"Saiag","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"ref-dst10216-10","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/S0190-9622(96)90297-2","article-title":"Renal involvement in toxic epidermal necrolysis.","volume":"34","author":"Blum","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"ref-dst10216-11","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1093\/ndt\/13.9.2182","article-title":"The renal risks of high-dose intravenous immunoglobulin treatment.","volume":"13","author":"Stahl","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"ref-dst10216-12","first-page":"901","article-title":"Reemergence of sucrose nephropathy: acute renal failure caused by high-dose intravenous immune globulin therapy.","volume":"93","author":"Zhang","year":"2000","journal-title":"South Med J"},{"key":"ref-dst10216-13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0140-6736(91)93395-P","article-title":"High-dose intravenous IgG treatment and renal function.","volume":"337","author":"Schifferli","year":"1991","journal-title":"Lancet"}],"container-title":["Archives of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/479147\/dst10216_33_36.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T17:00:51Z","timestamp":1577466051000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/479147"}},"subtitle":["A Prospective Noncomparative Study Showing No Benefit on Mortality or Progression"],"short-title":[],"issued":{"date-parts":[[2003,1,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/archderm.139.1.33","relation":{},"ISSN":["0003-987X"],"issn-type":[{"value":"0003-987X","type":"print"}],"subject":[],"published":{"date-parts":[[2003,1,1]]}}}